-
公开(公告)号:US20140343070A1
公开(公告)日:2014-11-20
申请号:US14450191
申请日:2014-08-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masahiro Kajino , Atsushi Hasuoka , Naoki Tarui , Terufumi Takagi
IPC: C07D207/48 , C07D409/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D401/04 , C07D405/12
CPC classification number: C07D207/48 , A61K31/4025 , A61K31/41 , A61K31/4439 , A61K31/501 , A61K31/506 , C07D207/335 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/12 , C07D487/04
Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug thereof is provided.
Abstract translation: 一种含有式(I)表示的化合物的质子泵抑制剂,其中X和Y相同或不同,并且各自是主链中的键或具有1至20个碳原子的间隔基,R 1是任选取代的烃基或 任选取代的杂环基,R 2,R 3和R 4相同或不同,各自为氢原子,任选取代的烃基,任选取代的噻吩基,任选取代的苯并[b]噻吩基,任选取代的呋喃基 ,任选取代的吡啶基,任选取代的吡唑基,任选取代的嘧啶基,酰基,卤素原子,氰基或硝基,R 5和R 6相同或不同,各自为氢原子或 任选取代的烃基,其具有优异的质子泵作用,并且在体内转化为质子泵抑制剂之后显示出抗溃疡活性等,或其中的盐 或其前药。
-
公开(公告)号:US10774083B2
公开(公告)日:2020-09-15
申请号:US16333296
申请日:2017-09-14
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Takaharu Hirayama , Yasuhiro Hirata , Yusuke Tominari , Naoki Iwamura , Yusuke Sasaki , Moriteru Asano , Terufumi Takagi , Masanori Okaniwa , Shinichi Imamura
IPC: C07D401/04 , C07D401/14 , C07D473/28 , C07D405/14 , C07D413/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D473/40 , C07D519/00 , A61P35/00 , A61K31/506 , A61K31/444 , A61K31/4439 , C07D473/00 , C07D473/32 , A61K31/5377 , A61K31/501 , A61K31/52 , A61P43/00 , A61K31/437 , C12N9/99
Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US09890145B2
公开(公告)日:2018-02-13
申请号:US15137161
申请日:2016-04-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masato Yoshida , Kazuaki Takami , Yusuke Tominari , Zenyu Shiokawa , Akito Shibuya , Yusuke Sasaki , Tony Gibson , Terufumi Takagi
IPC: C07D401/14 , C07D487/04 , C07D417/14 , C07D487/10 , A61P37/00 , C07D403/14 , A61K31/4155 , C07D413/14 , C07D401/04 , C07D409/14 , C07D405/14 , A61K9/06 , A61K9/20 , A61K9/48 , C07D403/04 , C07D471/04 , C07D471/10 , C07D491/107 , C07D495/04
CPC classification number: C07D413/14 , A61K9/06 , A61K9/2018 , A61K9/2054 , A61K9/4858 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/107 , C07D495/04
Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号:US10800754B2
公开(公告)日:2020-10-13
申请号:US16332993
申请日:2017-09-14
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Takaharu Hirayama , Yasuhiro Hirata , Yusuke Tominari , Naoki Iwamura , Yusuke Sasaki , Moriteru Asano , Terufumi Takagi , Masanori Okaniwa , Masato Yoshida , Shinichi Imamura
IPC: C07D401/04 , C07D401/14 , C07D407/14 , C07D409/14 , C07D417/14 , A61P35/00
Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US10696651B2
公开(公告)日:2020-06-30
申请号:US16323863
申请日:2017-08-09
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Jun Fujimoto , Xin Liu , Osamu Kurasawa , Terufumi Takagi , Douglas Robert Cary , Hiroshi Banno , Yasutomi Asano , Takuto Kojima
IPC: C07D401/12 , C07D403/12 , C07D401/14 , C07D213/75 , C07D405/12 , C07D239/42 , C07D241/12 , C07D471/04 , C07D498/04 , C07D213/65 , A61P35/00 , C07D241/20 , C07D213/73 , A61K31/53 , A61K31/505 , A61K31/4406 , A61K31/444 , A61K31/4965 , C07D213/68 , C07D213/42 , A61K31/506 , A61K31/497 , A61K31/4375 , C07D239/20 , A61P43/00 , A61K31/5383 , A61K31/437 , A61K31/44 , C07D253/06 , C07D231/12 , C07D239/30 , C07D239/34 , C07D239/48 , C07D253/07 , C07D409/12 , C07D487/04
Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US10308605B2
公开(公告)日:2019-06-04
申请号:US14450191
申请日:2014-08-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masahiro Kajino , Atsushi Hasuoka , Naoki Tarui , Terufumi Takagi
IPC: C07D207/48 , C07D409/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D401/04 , C07D405/12 , A61K31/4439 , A61K31/4025 , A61K31/41 , A61K31/501 , A61K31/506 , C07D207/335 , C07D403/04 , C07D405/04 , C07D409/12 , C07D487/04
Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug thereof is provided.
-
公开(公告)号:US09321757B2
公开(公告)日:2016-04-26
申请号:US14533326
申请日:2014-11-05
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masato Yoshida , Kazuaki Takami , Yusuke Tominari , Zenyu Shiokawa , Akito Shibuya , Yusuke Sasaki , Tony Gibson , Terufumi Takagi
IPC: C07D401/14 , C07D487/04 , C07D417/14 , C07D487/10 , A61P37/00 , C07D403/14 , A61K31/4155 , C07D413/14 , C07D409/14 , C07D405/14 , C07D401/04 , A61K9/06 , A61K9/20 , A61K9/48
CPC classification number: C07D413/14 , A61K9/06 , A61K9/2018 , A61K9/2054 , A61K9/4858 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/107 , C07D495/04
Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物,其可用于预防或治疗炎性疾病,自身免疫性疾病,骨关节炎性退行性疾病,肿瘤性疾病等,以及含有它们的药物。 本发明涉及由式(I)表示的化合物:其中每个符号如说明书中所定义,或其盐。
-
-
-
-
-
-